Immatics N.V. (IMTX) shareholders
Close on Nov 17, 2026Market cap $843.31MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 21,652,162 | 16.10% | 13G (passive) amendment | Mar 31, 2026 |
| Roderick Wong Joint filing with RTW Investments, LP (9.60%) | 12,869,340 | 9.60% | 13G (passive) amendment | Mar 31, 2026 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (7.60%), Perceptive Life Sciences Master Fund, Ltd. (7.60%) | 11,418,016 | 7.60% | 13D (active) amendment | Aug 26, 2026 |
| Aaron Cowen Joint filing with Suvretta Capital Management, LLC (8.30%), Averill Master Fund, Ltd (7.10%) | 11,190,129 | 8.30% | 13G (passive) amendment | Dec 31, 2025 |
| Baker Bros. Advisors LP Joint filing with Baker Bros. Advisors (GP) LLC (8.40%), Julian C. Baker (8.40%) and 1 more | 10,168,901 | 8.40% | 13G (passive) amendment | Jun 30, 2025 |
| Felix J. Baker Joint filing with Baker Bros. Advisors LP (7.00%), Baker Bros. Advisors (GP) LLC (7.00%) and 1 more | 9,508,565 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| Suvretta Capital Management, LLC Joint filing with Aaron Cowen (7.50%), Averill Master Fund, Ltd. (6.70%) | 9,135,029 | 7.50% | 13G (passive) amendment | Mar 31, 2025 |
| RTW Investments, LP Joint filing with Roderick Wong (7.30%) | 8,815,617 | 7.30% | 13G (passive) amendment | Sep 30, 2025 |
| Wellington Group Holdings LLP Joint filing with Wellington Management Group LLP (7.10%), Wellington Investment Advisors Holdings LLP (7.10%) and 1 more | 8,583,568 | 7.10% | 13G (passive) amendment | Mar 31, 2025 |
| The Toronto-Dominion Bank | 7,436,342 | 5.50% | 13G (passive) | Mar 31, 2026 |
| Baker Bros. Advisors (GP) LLC Joint filing with Baker Bros. Advisors LP (6.00%), Julian C. Baker (6.00%) and 1 more | 7,275,830 | 6.00% | 13G (passive) amendment | Dec 31, 2024 |
| Roderick Wong, M.D. Joint filing with RTW Investments, LP (5.50%) | 6,540,540 | 5.50% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 22,365,046 | 16.68% | $226.56M | +712,884 | 0.15% |
| Rtw Investments, LP | 12,946,176 | 9.66% | $131.14M | +76,836 | 1.12% |
| Suvretta Capital Management, LLC | 11,190,129 | 8.35% | $113.36M | – | 2.07% |
| Perceptive Advisors LLC | 10,383,456 | 7.74% | $105.18M | – | 1.58% |
| Baker Bros. Advisors LP | 9,508,565 | 7.09% | $96.32M | −1,408,128 | 0.48% |
| Jefferies Financial Group Inc. | 6,506,802 | 4.85% | $65.91M | +1,447,251 | 0.43% |
| Vestal Point Capital, LP | 6,175,000 | 4.61% | $62.55M | – | 1.46% |
| Sofinnova Investments, Inc. | 3,669,346 | 2.74% | $37.17M | +38,892 | 1.92% |
| Morgan Stanley | 2,186,494 | 1.63% | $22.15M | +37,412 | 0.00% |
| Citadel Advisors LLC | 1,814,657 | 1.35% | $18.38M | −37,306 | 0.00% |
| Wellington Management Group Llp | 1,647,852 | 1.23% | $16.69M | +85,960 | 0.00% |
| Point72 Asset Management, L.P. | 1,449,597 | 1.08% | $14.68M | −44,203 | 0.02% |
| Woodline Partners LP | 900,736 | 0.67% | $9.12M | −99,861 | 0.03% |
| Sphera Funds Management Ltd. | 720,057 | 0.54% | $7.29M | +23,952 | 0.95% |
| University Of Texas/Texas Am Investment Managment Co | 697,431 | 0.52% | $7.06M | – | 0.82% |
| abrdn plc | 653,604 | 0.49% | $6.62M | −167,113 | 0.01% |
| Qube Research & Technologies Ltd | 523,217 | 0.39% | $5.30M | +156,445 | 0.00% |
| Boxer Capital Management, LLC | 475,000 | 0.35% | $4.81M | New | 0.36% |
| TD Asset Management Inc | 449,348 | 0.34% | $4.55M | −21,096 | 0.00% |
| Wasatch Advisors LP | 441,510 | 0.33% | $4.47M | −23,313 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 83 | 100M | 74.4% | 12 / 25 | 33 / 13 | 4M | 12M |
| Q1 2026 | 84 | 108M | 80.7% | 15 / 27 | 24 / 6 | 12M | 10M |
| Q4 2025 | 75 | 106M | 79.4% | 19 / 27 | 21 / 7 | 24M | 10M |
| Q3 2025 | 63 | 93M | 69.0% | 9 / 17 | 21 / 16 | 11M | 11M |
| Q2 2025 | 70 | 93M | 69.4% | 17 / 24 | 17 / 23 | 16M | 14M |
| Q1 2025 | 76 | 91M | 68.1% | 15 / 24 | 21 / 24 | 16M | 17M |
| Q4 2024 | 85 | 92M | 68.8% | 17 / 34 | 24 / 23 | 26M | 10M |
| Q3 2024 | 91 | 76M | 56.8% | 16 / 17 | 42 / 13 | 7M | 7M |
| Q2 2024 | 90 | 78M | 58.0% | 23 / 30 | 26 / 10 | 14M | 10M |
| Q1 2024 | 77 | 73M | 54.6% | 18 / 29 | 23 / 17 | 28M | 8M |
| Q4 2023 | 76 | 52M | 39.1% | 13 / 34 | 20 / 11 | 12M | 4M |
| Q3 2023 | 74 | 45M | 33.5% | 11 / 32 | 18 / 5 | 7M | 3M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jasuja Harpreet Singh | Chief Executive Officer, Director | 217,241 | 0.16% | Mar 18, 2026 |
| James Nelson Pepin | Gen Counsel and Corp Secretary | – | – | Aug 18, 2026 |
| Jordan Zeik Silverstein | Head of Strategy | 7,826 | 0.01% | Mar 18, 2026 |
| Cedrik Michael Britten | Chief Medical Officer | 250 | 0.00% | Mar 18, 2026 |
| Amie Elizabeth Krause | Chief People Officer | – | – | Mar 18, 2026 |
| Carsten Alexander Johannes Reinhardt | Chief Development Officer | 47,781 | 0.04% | Mar 18, 2026 |
| Steffen Martin Walter | Chief Operating Officer | 10,000 | 0.01% | Mar 18, 2026 |
| Venkat Ramanan | Chief Financial Officer | – | – | Mar 18, 2026 |
| Rainer Kramer | Chief Business Officer | – | – | Mar 18, 2026 |
| Toni Michael Weinschenk | Chief Innovation Officer | – | – | Mar 18, 2026 |
| Edward A. Sturchio Jr | General Counsel | – | – | Mar 18, 2026 |
| Advisors Llc Perceptive | Director | – | – | Aug 27, 2026 |
| Joseph Edelman | Director | 11,246,516 | 8.39% | Aug 27, 2026 |
| Life Sciences Master Fund Ltd Perceptive | Director | – | – | Aug 27, 2026 |
| Alise Reicin | Director | – | – | Jun 18, 2026 |
| Eliot Forster | Director | – | – | Jun 18, 2026 |
| Michael G. Atieh | Director | – | – | Jun 18, 2026 |
| Heather L. Mason | Director | – | – | Jun 18, 2026 |
| Paul Rutherford Carter | Director | – | – | Jun 18, 2026 |
| Peter Alan Chambre | Director | 105,987 | 0.08% | Jun 18, 2026 |
| Mathias Hothum | Director | 329,521 | 0.25% | Jun 18, 2026 |
| Adam Leo Stone | Director | – | – | Jun 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joseph Edelman Director | Aug 26, 2026 | Buy | +863,060 | $8.69 | $7.50M | 11,246,516 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Immatics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 259,564 shares on Aug 28, 2026 over the last 90 days.
See a number that looks wrong?